New drug duo targets hard-to-treat leukemias in early trial

NCT ID NCT07356154

First seen Jan 27, 2026 · Last updated Jun 18, 2026 · Updated 23 times

Summary

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and see if the combination can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Cancer Center (Data collection only)

    NOT_YET_RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-••••

  • MD Anderson Cancer Center (Data Collection Only)

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Bergen (All Protocol Activities)

    RECRUITING

    Montvale, New Jersey, 07645, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Monmouth (All Protocol Activities)

    RECRUITING

    Middletown, New Jersey, 07748, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Nassau (All Protocol Activities)

    RECRUITING

    Rockville Centre, New York, 11553, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)

    RECRUITING

    Commack, New York, 11725, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    RECRUITING

    Harrison, New York, 10604, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

    Contact Phone: •••-•••-••••

  • University of North Carolina (Data Collection Only)

    NOT_YET_RECRUITING

    Chapel Hill, North Carolina, 27514, United States

    Contact Phone: •••-•••-••••

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute leukemia acute lymphoblastic leukemia acute myeloid leukemia leukemia mixed phenotype acute leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.